Tempest Therapeutics
TPST
41 hedge funds and large institutions have $57.5M invested in Tempest Therapeutics in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
8% more funds holding
Funds holding: 38 → 41 (+3)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
37% less capital invested
Capital invested by funds: $90.7M → $57.5M (-$33.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$1.17M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$586K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$563K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$321K |
| 5 |
State Street
Boston,
Massachusetts
|
+$237K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$897K |
| 2 |
ASP
Adams Street Partners
Chicago,
Illinois
|
-$341K |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$181K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$123K |
| 5 |
Renaissance Technologies
New York
|
-$63K |
TPST Hedge Fund Activity: Q3 2019 in Review
41 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2019, worth a combined $57.5M — down 37% from $90.7M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TPST positions and 2 closed out — a net gain of 3 holders — while 13 added to existing stakes and 8 trimmed.
The largest buyer was Samsara BioCapital, adding an estimated $1.17M. The largest seller was AWM Investment Company, exiting entirely with an estimated $897K sold.
- 41 institutional investors held Tempest Therapeutics (TPST) as of Q3 2019, up from 38 in Q2 2019.
- Funds reported $57.5M of Tempest Therapeutics stock for Q3 2019, down 37% quarter-over-quarter.
- 5 funds opened new Tempest Therapeutics positions in Q3 2019 and 2 closed out, a net change of +3 holders.
- The largest Tempest Therapeutics buyer in Q3 2019 was Samsara BioCapital, an estimated $1.17M added.
- The largest Tempest Therapeutics seller in Q3 2019 was AWM Investment Company, an estimated $897K sold.
Based on aggregated 13F filings for Q3 2019.